Spotlight: N,N-dimethyltryptamine (DMT) mitigates experimental stroke by stabilizing the blood-brain barrier and reducing neuroinflammation (László, et al, 2025)

"...evidence suggests that the use of serotonergic and non-serotonergic psychedelics (ketamine) for the treatment of SUD may provide advantages over traditional therapeutics, and these compounds may eventually become part of the next generation of treatments for SUD under specific circumstances."

"Serotonergic psychedelics & ketamine appear to share common cellular mechanisms. They both recruit glutamatergic neurons to stimulate BDNF-trKB signaling, promoting synaptogenesis via the mTOR pathway. These changes may explain their efficacy in depression, anxiety, PTSD, & addiction."

"findings suggest ketamine modulates brain network dynamics which may normalize dynamic patterns seen in TRD at baseline toward patterns seen in controls. Changes in Salience Network state dynamics may correspond to improvements in ruminative symptoms following ketamine therapy."

"Psychedelics may be a potential alternative therapy for treatment-resistant depression. LSD has a complex mode of action which is not yet fully understood. Low doses of LSD can drastically increase brain plasticity."

"results suggest that long-term Ayahuasca use may be linked to lasting changes in emotional regulation and brain function, potentially supporting psychological well-being."

"Concurrent psychotherapy improved treatment maintenance. Adverse events were generally mild to moderate... Ketamine maintenance therapy shows promise as a treatment option for TRD, with regular dosing schedules and early intervention associated with optimal outcomes."